logo-loader
AusCann Group Holdings Ltd

AusCann Group secures supplier of cannabis resin for upcoming manufacturing

AC8 has all the necessary licenses to grow and manufacture cannabinoid medicines in Australia.

medical cannabis concept
The company's first product line is medicinal cannabis hard shell capsules to treat chronic pain

AusCann Group Holdings Ltd (ASX:AC8) has entered into a supply agreement to purchase cannabis resin from MediPharm Labs Corporation (TSXV:LABS) (OTCQB:MLCPF).

The high-grade cannabis resin will primarily be used in the manufacture of AusCann’s first product line of hard-shell cannabinoid capsules.

MediPharm is Canada’s largest and most experienced supplier of purified, pharmaceutical grade cannabis extracts.

Its state-of-the-art facility is one of the most innovative and technically advanced in the cannabis industry.

First supply under the deal is set to commence in the coming months.

READ: AusCann Group on track to produce cannabinoid medicines this year

AusCann’s interim CEO Dr Paul MacLeman said: “Reliable supply of pharma-grade cannabinoid extracts through MediPharm’s proprietary methodologies will support AusCann’s ability to develop and deliver quality cannabinoid medicines.

"Critical for the company are repeatability in manufacturing, reliable dosing, and purity assurance.

“These product foundations will allow delivery of effective, trusted and safe medicines for the treatment of chronic pain.”

Plans for multiple suppliers to lower risk

AusCann is working towards securing a small number of validated, safe and reliable sources of cannabis resins as ongoing inputs into its pharmaceutical product development, clinical trials and product sales activities.

This multi-supplier strategy mitigates and reduces supply risks and enables AusCann to work efficiently with specialists in different types of extracts across a number of jurisdictions.

It also supports AusCann’s focus upon novel dose form development to optimise patient outcomes and create valuable pharmaceutical products for the Australian and export markets.

Quick facts: AusCann Group Holdings Ltd

Price: $0.37

Market: ASX
Market Cap: $115.72 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AusCann Group Holdings Ltd named herein, including the promotion by the Company of AusCann Group Holdings Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Auscann targeting pain management with Australian cannabinoid products

Elaine Darby, managing director of Auscann Group Holdings Ltd (ASX:AC8), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney. Auscann is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019....

on 6/9/18

2 min read